Zinaida Good

Assistant Professor of Medicine at Stanford University

[Zinaida Good @GoodZinaida]

Grateful to the Stanford Center for Digital Health for supporting our work with @jure on prototyping AI models and agents for T cell therapy design.

[Stanford Center for Digital Health @StanfordCDH]

We're excited to introduce the 2026 Stanford Center for Digital Health Grant Awardees, a cohort of scientists working on projects that can transform health. Please join us in celebrating this exceptional group of researchers from across @stanford. https://t.co/hcej9XTbxE

[Laude Institute @LaudeInstitute]

We asked the best AI researchers in the world one question: if you had the resources, how would you use AI to solve humanity's hardest problems?

Today we're sharing what came back.

Moonshots // ONE is live. 🧵 https://t.co/tMRWDNOXaU

[Roth_Lab @Roth_Lab]

Excited to present the first major work after starting our lab at Stanford and the Arc this year: CRISPR-All, a unified genetic perturbation language for programming any major type of genetic perturbation simultaneously, in any combination, at genome scale, in human cells.

[Zinaida Good @GoodZinaida]

We're excited to release tcellMIL, an attention-based multiple instance learning model for predicting patient outcomes after CAR T cell therapy for lymphoma and nominating cell design strategies in #neurips2025 AI4D3! https://t.co/3WJBQmJ3W5

[Zinaida Good @GoodZinaida]

It's exciting to share our mini-review on #Treg cell therapies out today in Frontiers in Immunology! Earning a #NobelPrize this year, Tregs have been tested in >69 clinical trials and are moving towards initial approvals. https://t.co/4JdEWamiDO

[Zinaida Good @GoodZinaida]

This would not be possible without my mentors, especially Crystal Mackall, @sylviaplevritis, @GarryPNolan, Sean Bendall, David Miklos, and Michael Gold - THANK YOU!

[Zinaida Good @GoodZinaida]

Today is my first day as an Assistant Professor of Medicine at Stanford University! My research program is focused on understanding and enhancing engineered T cell immunotherapies for cancer and immune-mediated diseases. If interested in joining please reach out!

[Zinaida Good @GoodZinaida]

Very proud of Anne Marijn Kramer to present 2 orals and a poster at #ASH2024, especially our work on CD22-CAR!
Session 702
Dec 9 at 2:45 PM
San Diego Convention Center, Room 6CF
Title: CD22-Directed CAR T Cell Single Cell Multiomic Features Associated with IEC-HS

[Zinaida Good @GoodZinaida]

So proud of Kelvin Mo to give his first talk at #ASH2024!
Session 702
Dec 7 at 4:00 PM
Manchester Grand Hyatt San Diego, Grand Hall C
Title: CCL8/CCL13-Producing Tumor-Associated Macrophages Linked to Poor Outcomes after CAR T Cell Therapy for LBCL

[Zinaida Good @GoodZinaida]

What an honor to give my first invited talk at #ASH2024. I am so grateful to my mentors Crystal Mackall, Sylvia Plevritis, and David Miklos for enabling me to get here!
Dec 8 at 4:30 PM, San Diego Conv. Center, Room 33
Cellular Heterogeneity and Relationship to Clinical Outcomes

[Zinaida Good @GoodZinaida]

Our Stanford Center for Cancer Cell Therapy is excited to offer a Postdoctoral Fellow position at the interface between machine learning and T cell therapies: https://t.co/09PosFUrGz

[Cee Cee Schnugg @ceeceeboom]

Boom Capital is hiring a Chief of Staff. 🚀 This is one of our most important hires. You'll liaise with our in-house scientific society and impact every aspect of a VC firm, serving unprecedented ideas, scientists and engineers. Join https://t.co/TevnrYs5d5 and apply here: https://t.co/Td1hBN9SBE

[Zinaida Good @GoodZinaida]

Grateful to give an invited talk at the 6th Annual #Treg-Directed Therapies Summit! Please join us in Boston this May 21-23.
https://t.co/7gzWIYGwVP

[Zinaida Good @GoodZinaida]

@CalebLareau @Nature @Satpathology CONGRATS @CalebLareau and @Satpathology!

[Zinaida Good @GoodZinaida]

Humbled and grateful to be selected as a 2023 Bridge Fellow by the @parkerici to push forward CAR T immunotherapy research. https://t.co/RyuZKdOAor

[Zinaida Good @GoodZinaida]

Grateful to @CGT_Live to publish this summary of our work with @MackallLab, David Miklos, @BitaSahaf and team that I presented at @AACR! https://t.co/AjuISwjkcp

[Zinaida Good @GoodZinaida]

Honored to be interviewed by @10xGenomics to discuss our work with @SRamakrishna_MD , @MackallLab, and @michelle_monje on GD2-CAR T cell therapy for pediatric brain cancer.

[10x Genomics @10xGenomics]

#CART therapy is a good treatment for blood cancers, and @SRamakrishna_MD and @GoodZinaida think it has potential for kids with fatal brain cancer, too. Hear more about their #singlecell study, in collaboration with @parkerici, in our latest blog post ⬇️ https://t.co/XO7SshaiyB

[Zinaida Good @GoodZinaida]

Thanks @TeikoBio for highlighting our work with @jayspiegel25, @BitaSahaf, @MackallLab, David Miklos, and team on defining the role of CAR Treg cells in progression following #CART therapy for lymphoma.

[Teiko @TeikoLabsHQ]

Axi-cel is effective in only 40% of large B cell lymphoma (LBCL) patients and 69% experience neurotoxicity. Using mass cytometry, @GoodZinaida et al profiled post-infusion CAR T cells in LBCL patients to identify markers of response and neurotoxicity. https://t.co/arfwdboS59

[Zinaida Good @GoodZinaida]

@KoleRoybal @apwiita @dbgoodman @CamilliaAzimi Congrats Kole, Dan, and team!!

[Zinaida Good @GoodZinaida]

Thanks to @statnews for covering our work identifying CAR Treg cells as limiting efficacy, toxicity, and expansion of CD19-CAR in lymphoma. Full article in @NatureMedicine here: https://t.co/eXErZXEAQs. https://t.co/hK8dV2XUe3